SecBot SecBot

ABT

ABBOTT LABORATORIES
NYSE· Pharmaceutical Preparations· Inc. IL· CIK 0000001800 Biotech & Drug Discovery
$107.95 −0.57 (−0.53%)
Nov 16 4:00 PM ET · prev $108.52
Market cap
$185.8B
Large cap
Consensus
Buy
79% Buy or better · 33 analysts
Median target
$120.00
+11% · range $100.00–130.00
1 year
−17.0%
from $130.03 · Nov 17
30 days
+2.9%
from $104.89
52-week range
$82.56–130.03
−17% from high · low May 11
Avg volume 20D
9.23M
shares / day
Short interest
19.06M
≈1.1% of shares · +9.6%
Days to cover
1.9
at average volume
Insider net
−$46.0M
3 buyers · 4 sellers · since Mar 2
New fund stakes
4
Q2 2026 13F · 3 exits
Reddit crowd
50°
Neutral · 3 mentions this week
SecBot read MIXED 18 reports · 90 days
Balance 1 bearish · 4 bullish · 2 mixed · 11 neutral oldest → newest, height = score
Avg score ·High conf. 12/18

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders bought $1.3M at an average $91.65. 4 insiders sold $47.3M. Price is 18% above their cost.

  • InstitutionsMIXED

    Q2 2026: 61 added (4 new), 60 trimmed or exited. Largest new: Barrow Hanley Mewhinney & Strauss $324.0M, Point72 Asset Management, $140.8M.

  • AnalystsBULLISH

    26 of 33 rate it Buy or better. Median target $120.00 (+11%).

  • Short sellersSTEADY

    Short interest +9.6% to 19.06M shares. 1.9 days to cover, ≈1.1% of shares.

  • TrendUPTREND

    4% above its 50-day average.

  • SocialQUIET

    Crowd 50° (neutral) this week from 3 mentions: 0 bullish, 0 bearish. No setup is alerting.

Who's buying

13F· Q2 2026
4
new positions
3
exits
$696.2M
in new stakes
FundMoveSharesValue
CHARLES SCHWAB INVESTMENT MANAGEMENT INCADD59,674,507$5.4B
Capital Research Global InvestorsTRIM36,908,990$3.3B
PRICE T ROWE ASSOCIATES INC /MD/ADD22,787,202$2.1B
JPMORGAN CHASE & COTRIM15,095,898$1.4B
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPADD10,897,178$988.8M
FLOSSBACH VON STORCH SEADD9,950,828$902.9M
CITADEL ADVISORS LLCDOUBLED8,597,227$780.1M
WELLINGTON MANAGEMENT GROUP LLPTRIM8,304,709$753.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

33 analysts
Buy 79% rate it Buy or better
Strong Buy11Buy15Hold7Sell0Strong Sell0
12-month targets · 26 analysts

Price is inside the target range. Median implies +11%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Oct 27, 2026Argus Research
DOWNGRADE
DOWNGRADEHold
Oct 23, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight
Oct 22, 2026Citigroup
MAINTAIN
MAINTAINBuy
Oct 22, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Oct 22, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight
Oct 22, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Congressional trades
ABT trades disclosed by members of Congress, with disclosure delay.
12 members · 12 buys / 13 sells
DateMemberType AmountDisclosed
Oct 7, 2026 Ro KhannaDHouse Spouse account · Abbott Laboratories BUY $15K–$50K Nov 5, 2026 +29d
Oct 2, 2026 Pete SessionsRHouse Spouse account · Abbott Laboratories SELL $50K–$100K Oct 27, 2026 +25d
Sep 18, 2026 Gilbert CisnerosDHouse Abbott Laboratories BUY $1K–$15K Oct 12, 2026 +24d
Sep 17, 2026 Thomas Kean JrRHouse Abbott Laboratories SELL $1K–$15K Oct 30, 2026 +43d
Sep 4, 2026 Ro KhannaDHouse Spouse account · Abbott Laboratories BUY $1K–$15K Oct 7, 2026 +33d
Jul 30, 2026 Rich McCormickRHouse Abbott Laboratories SELL $1K–$15K Aug 14, 2026 +15d
Jul 17, 2026 Mike KellyRHouse Spouse account · Abbott Laboratories SELL $1K–$15K Aug 12, 2026 +26d
Jul 14, 2026 Rick AllenRHouse Spouse account · Abbott Laboratories SELL $15K–$50K Aug 18, 2026 +35d
Jul 8, 2026 Rick LarsenDHouse Abbott Laboratories SELL $1K–$15K Jul 12, 2026 +4d
Jun 16, 2026 Gilbert CisnerosDHouse Abbott Laboratories BUY $1K–$15K Jul 2, 2026 +16d

Insider ledger

Form 4
$1.3M
bought · 3 insiders
$47.3M
sold · 4 insiders
+17.8%
vs their $91.65 cost
DateInsiderTypeValue
Nov 5, 2026
Moreland Mary K
EXECUTIVE VICE PRESIDENT
Nov 5, 2026
SELL$406.0K
Sep 30, 2026
Conroy Kevin T
Director
Sep 30, 2026
AWARD$31.4K
Sep 30, 2026
Stratton John G
Director
Sep 30, 2026
AWARD$39.2K
Sep 30, 2026
Roman Michael F
Director
Sep 30, 2026
AWARD$37.7K
Sep 30, 2026
Gonzalez Patricia Paola
Director
Sep 30, 2026
AWARD$32.9K
Sep 30, 2026
Ahuja Nita
Director
Sep 30, 2026
AWARD$31.4K
Sep 23, 2026
Conroy Kevin T
Director
Sep 23, 2026
TAX W/H$5.5M
Sep 2, 2026
MCCOY JOHN A. JR.
VICE PRESIDENT AND CONTROLLER
Sep 2, 2026
SELL$3.0K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 27, 2026
Enforcement
Taylor et al v. Abbott Diabetes Care Inc.
Court ruling (cand). Docket: 4:26-cv-00003
Oct 21, 2026
Earnings
Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent Third-quarter GAAP diluted EPS of $0.53; adjusted…
Oct 21, 2026
Earnings result
ABT Q3 2026 Earnings: EPS $1.42 (-0.7% vs est)
Oct 20, 2026
Enforcement
Rapacon v. Abbott Laboratories
Court ruling (cand), Docket: 4:26-cv-00311
Oct 16, 2026
Enforcement
Ghosh v. Abbott Laboratories, Inc. et al
Court ruling (hid), Docket: 1:26-cv-00264

Washington

Corporate Lobbying

85 lobbying filings and 12 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
19,058,208
shares short
+9.6%
vs prior settlement
1.9
days to cover
≈1.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 5, 2026 SEC
Analysis based on filing metadata only; document content was unavailable. A Form 144 was filed for Abbott Laboratories…
144 · Impact 2/10
Nov 5, 2026 Insider
Moreland Mary K sold 3,500 shares
EXECUTIVE VICE PRESIDENT @ $116.00 ($406.0K)
Oct 27, 2026 SEC
Argus Research downgrades ABT to Hold, PT not provided
ANALYST-DOWNGRADE · Impact 2/10
Oct 27, 2026 SEC
The court entered a stipulated ESI discovery protocol in a consumer class action against Abbott Diabetes Care Inc. and…
COURT-RULING · Impact 1/10
Oct 27, 2026 Event
Taylor et al v. Abbott Diabetes Care Inc.
Court ruling (cand). Docket: 4:26-cv-00003
Oct 21, 2026 Earnings
Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent Third-qu
Oct 7, 2026 Congress
Ro Khanna buy
$15,001 - $50,000 · House
Oct 2, 2026 Congress
Pete Sessions sell
$50,001 - $100,000 · House
Reddit Mentions per day, 14 days
Crowd this week 50° Neutral 0 bullish · 0 bearish
Mentions, 7 days 3 0 in posts · 3 in comments
Recent posts
Recent comments
All social signals and their track records

SecBot reports

37 filings · 1 press release · 8 bullish · 2 bearish · 3 mixed · 24 neutral
All ABT filing & press-release reports (38)